A Phase 1 Target Occupancy PET Study of Xanamem
Phase of Trial: Phase I
Latest Information Update: 03 Jul 2019
Price : $35 *
At a glance
- Drugs UE 2343 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- 03 Jul 2019 According to an Actinogen Medical media release, the study has now completed the 20mg cohort and the Company is pleased to confirm that the results continue to be encouraging, with this dose also demonstrating significant inhibition of the 11beta-HSD1 enzyme. The study will now proceed with 30mg and 5mg cohorts, to enable a full analysis and understanding of the dose-inhibition response of Xanamem.
- 26 Jun 2019 Results (10mg ) presented in an Actinogen Medical media release.
- 26 Jun 2019 According to an Actinogen Medical media release, further results are expected by mid Q3 and Q4 CY2019.